Additionally, ErbB2 activation can upregulate GLS1 expression in breast cancer cells through a mechanism controlled by the NF-κB pathway rather than by c-Myc, promoting glutamine utilization in cancer cells (Qie et al., 2014). Here, GLS is linked to breast cancer.